Vanderbilt-Ingram Cancer Center (VlCC) is a matrix cancer center within Vanderbilt University. VlCC trials been part of the cooperative group system for 24 years, as a member of the Eastern Cooperative Oncology Group, the Gynecologic Oncology Group (GOG) and the American College of Surgeons Oncology Group (ACOSOG). In this role, we have integrated our physicians into leadership roles and our science into the clinical trials and accrued patients into trials. The VlCC selected Jordan Berlin, MD, as PI to lead the efforts of the institution to integrate its scientific, academic and patient resourcs into the new NCTN. He has been involved extensively In the cooperative groups in both clinical trials and leadership. He has also been a successful mentor. To maintain a broad representation across medical disciplines and disease interests, two leadership boards were created. The internal advisory board (lAB) assures the optimum use of the grant such as budget review, assuring multidisciplinary involvement and participation throughout the NCTN while the NCTN Executive Committee (NEC) implements operational functions such as trial opening, accrual, and mentoring. Both the lAB and NEC will work to integrate VlCC science into the NCTN. The VlCC Clinical Trials Shared Resource and its NCTN team will ensure that regulatory and biospecimen/radiology data submissions are timely and highly accurate. VlCC has a long track record of leadership, both scientific and administrative, within the cooperative groups, integrating basic science into clinical trials and helping junior faculty in trial development. VlC brings great strengths to the NCTN including two SPORE grants, two EDRN grants, a world class Institute of Imaging Science, advanced capabilities in proteomics and a superb Center for Quantitative Sciences. Our Personalized Cancer Medicine Initiative is dedicated to answering Provocative Question B5 (How does the order in which mutations or epigenetic changes occur alter cancer phenotypes or affect the efficacy of targeted therapies?), and bringing the data from drug resistance-associated mutations into clinical trials. This is complemented by MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations The team of VlCC scientists, academic leaders and junior Investigators will significantly contribute to the NCTN goals and, as a result, improve the outcomes for cancer patients.
This grant provides the opportunity for Vanderbilt-Ingram Cancer Center (VlCC) to participate in the National Clinical Trials Network (NCTN). It supports the infrastructure at VlCC for the conduct of NCTN trials, thus allowing our investigators to collaborate with others around the country, to serve in leadership roles in the NCTN, to bring scientific discoveries from VlCC into NCTN trials and to mentor the next generation of clinical investigators In the NCTN system.
|Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594|
|Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697|
|Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121|
|Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087|
|Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154|
|Berlin, Jordan D; Feng, Yang; Catalano, Paul et al. (2018) An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 94:39-46|
|Goff, Laura W; Azad, Nilofer S; Stein, Stacey et al. (2018) Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Invest New Drugs :|
|Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855|
|Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382|
Showing the most recent 10 out of 22 publications